FDA clearance enabled clinical development for Nxera Pharma, which operates in key locations including Cambridge, Basel, and Seoul.
1 report, 0 independent
Updated Jul 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA clearance enabled clinical development for Nxera Pharma, which operates in key locations including Cambridge, Basel, and Seoul.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Nxera Pharma
company in Tokyo, Japan
Nothing else this week.
Related events
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
- A study author is based in Johns Hopkins School of Medicine, and the research is connected to Baltimore, now involving the FDA for drug approval.
Coverage
Newest first; wire copies grouped- Unknown outlet